Psychedelic perceptions: mental health service user attitudes to psilocybin therapy Kate Corrigan · Maeve Haran · Conor McCandliss · Roisin McManus · Shannon Cleary · Rebecca Trant · Yazeed Kelly · Kathryn Ledden · Gavin Rush · Veronica O’Keane · John R. Kelly Irish Journal of Medical Science (1971 -), 2021, 1-13. Doi : 10.1007/s11845-021-02668-2 Abstract Introduction : Despite the rapid advance of psychedelic science and possible translation of psychedelic therapy into the psychiatric clinic, very little is known about mental health service user attitudes. Objectives : To explore mental health service user attitudes to psychedelics and psilocybin therapy. Methods : A questionnaire capturing demographics, diagnoses, previous [...]
Lire la suiteLearning to Let Go : A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance Max Wolff, Ricarda Evens, Lea J. Mertens, Michael Koslowski, Felix Betzler, Gerhard Gründer and Henrik Jungaberle Frontiers in Psychiatry, February 2020 | Volume 11 | Article 5, 1-13. doi : 10.3389/fpsyt.2020.00005 The efficacy of psychedelic-assisted therapies for mental disorders has been attributed to the lasting change from experiential avoidance to acceptance that these treatments appear to facilitate. This article presents a conceptual model that specifies potential psychological mechanisms underlying such change, and that shows substantial parallels between psychedelic therapy and cognitive behavioral therapy: We propose that in the carefully controlled [...]
Lire la suitePsychedelic Medicines for Mood Disorders Current Evidence and Clinical Considerations Jerome Sarris; Diego Pinzon Rubiano; Kimberley Day; Nicole L. Galvão-Coelho; Daniel Perkins Current Opinion in Psychiatry, 2022, 35, (1), 22-29. doi : 10.1097/YCO.0000000000000759 https://www.medscape.com/viewarticle/964245 Abstract and Introduction Abstract Purpose of Review: Despite advances in treatment modalities for mood disorders over recent decades, further therapeutic options are still required. Increased research is occurring, with the pursuit of psychedelic-based pharmacotherapies for a range of mood disorders and other conditions. Recent Findings: Serotonergic psychedelics have been found to modulate brain networks underlying various psychiatric disorders, as well promoting neurogenesis and neuroplasticity. Randomized placebo-controlled trials have found psilocybin with psychological support effective at [...]
Lire la suiteNovel Treatment Approaches for Substance Use Disorders : Therapeutic Use of Psychedelics and the Role of Psychotherapy Michael Koslowski, Matthew W. Johnson, Gerhard Gründer, Felix Betzler Current Addiction Reports, 2021, 1-11. doi : 10.1007/s40429-021-00401-8 Abstract Purpose of Review : The use of psychedelics in a therapeutical setting has been reported for the treatment of various diagnoses in recent years. However, as psychedelic substances are still commonly known for their (illicit) recreational use, it may seem counterintuitive to use psychedelic therapy to treat substance use disorders. This review aims to discuss how psychedelics can promote and intensify psychotherapeutic key processes, in different approaches like psychodynamic and [...]
Lire la suiteMolecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans Paul Cumming, Milan Scheidegger, Dario Dornbierer, Mikael Palner, Boris B. Quednow and Chantal Martin-Soelch Molecules, 2021, 26, 2451 doi : 10.3390/molecules26092451 Abstract : Hallucinogens are a loosely defined group of compounds including LSD, N,Ndimethyltryptamines, mescaline, psilocybin/psilocin, and 2,5-dimethoxy-4-methamphetamine (DOM), which can evoke intense visual and emotional experiences. We are witnessing a renaissance of research interest in hallucinogens, driven by increasing awareness of their psychotherapeutic potential. As such, we now present a narrative review of the literature on hallucinogen binding in vitro and ex vivo, and the various molecular imaging studies with positron [...]
Lire la suiteEvolution historique et place du concept de psychothérapie dans les thérapies psychédéliques. Revue de la Littérature. Colloque ATHS, Biarritz, 22 octobre 2021. Dr Christian SUEUR Psychiatre, addictologue, praticien hospitalier Président du GRECC Nous allons, dans une revue de la littérature sur la médecine psychédélique, tenter de repérer les concepts intégrés dans la sémantique employée dans cette littérature, et l’évolution de la notion de psychothérapie, au cours de l’histoire : au début des années 1950 1960, le concept de « thérapie psychédélique » n’existe pas : les thérapies sont intimement liées à administration de LSD (et dans une moindre mesure de mescaline), et, soit il s’agit d’observations cliniques, psychiatrique avec peu [...]
Lire la suiteLSD, madness and healing : Mystical experiences as possible link between psychosis model and therapy model Isabel Wießner, Marcelo Falchi, Fernanda Palhano-Fontes, Amanda Feilding, Sidarta Ribeiro and Luís Fernando Tófoli Psychological Medicine, 2021, 1-15. Doi : 10.1017/S0033291721002531 Abstract Background : For a century, psychedelics have been investigated as models of psychosis for demonstrating phenomenological similarities with psychotic experiences and as therapeutic models for treating depression, anxiety, and substance use disorders. This study sought to explore this paradoxical relationship connecting key parameters of the psychotic experience, psychotherapy, and psychedelic experience. Methods : In a randomized, double-blind, placebo-controlled, crossover design, 24 healthy volunteers received 50 μg D-lysergic acid diethylamide (LSD) or inactive placebo. [...]
Lire la suiteTransient Stimulation with Psychoplastogens Is Sufficient to Initiate Neuronal Growth Calvin Ly, Alexandra C. Greb, Maxemiliano V. Vargas, Whitney C. Duim, Ana Cristina G. Grodzki, Pamela J. Lein, and David E. Olson ACS Pharmacology and Translational Science, 2020. doi : 10.1021/acsptsci.0c00065 ABSTRACT Cortical neuron atrophy is a hallmark of depression and includes neurite retraction, dendritic spine loss, and decreased synaptic density. Psychoplastogens, small molecules capable of rapidly promoting cortical neuron growth, have been hypothesized to produce long-lasting positive effects on behavior by rectifying these deleterious structural and functional changes. Here we demonstrate that ketamine and LSD, psychoplastogens from two structurally distinct chemical classes, promote [...]
Lire la suiteMarginalisation, stigmatisation et abandon du LSD en médecine Zoë Dubus Histoire, médecine et santé, 2019, 15, 87-105 Doi : 10.4000/hms.2168 https://journals.openedition.org/hms/2168 Abstracts Après avoir été l’une des substances pharmacologiques les plus étudiées des années 1950-1970, le LSD, puissant psychédélique ayant de nombreuses indications thérapeutiques, est abandonné par la communauté scientifique internationale au début des années 1970. Si des facteurs externes à la médecine ont eu un impact sur le déclin de ce médicament, il est également nécessaire de s’interroger sur les causes internes de ce rejet. Pour ce faire, une littérature anglo-saxonne émerge ces dernières années dans le champ des psychedelic studies, que nous enrichissons ici par une [...]
Lire la suitePositive expectations predict improved mental-health outcomes linked to psychedelic microdosing, KAERTNER L.S., STEINBORN M.B., KETTNER H., SPRIGGS M.J., ROSEMAN L., BUCHBORN T., BALAET M., TIMMERMANN C., ERRITZOE D., CARHARDT-HARRIS R.L. : Nature, 2021, 11, 1941 Doi : 1038/s41598-021-81446-7 Abstract Psychedelic microdosing describes the ingestion of near-threshold perceptible doses of classic psychedelic substances. Anecdotal reports and observational studies suggest that microdosing may promote positive mood and well-being, but recent placebo-controlled studies failed to find compelling evidence for this. The present study collected web-based mental health and related data using a prospective (before, during and after) design. Individuals planning a weekly microdosing regimen completed surveys at strategic [...]
Lire la suite